QQ4 2024 results for Clearbridge Health Limited show a modest sequential revenue improvement but persistent profitability pressures. Revenue rose to SGD 2.501 million in Q4 from SGD 2.273 million in Q2, a roughly 10% QoQ increase, while gross profit reached SGD 1.218 million translating to a gross margin of 48.7%. However, the company posted an operating loss of SGD 0.72 million and a net loss of SGD 0.784 million for the quarter, driven by SGD 1.822 million of other expenses alongside SGD 0.273 million of depreciation and amortization and SGD 0.165 million of-interest expense. EBITDA remained negative at SGD -0.428 million, signaling that EBITDA-level profitability has not yet turned positive despite top-line gains. On the balance sheet, cash and cash equivalents stood at SGD 3.168 million at year-end, with total liabilities of SGD 10.17 million and total stockholders’ equity of SGD 9.22 million, implying a net debt position of SGD 3.07 million. Operating cash flow was SGD 0.166 million for the quarter, and free cash flow was SGD 0.102 million, underscoring limited cash generation in the business while financing activities contributed SGD 1.266 million. Management commentary from the earnings call is not included in the provided data, limiting qualitative insights on strategic initiatives. Overall, the near-term uncertainty remains given negative profitability and working-capital pressures, even as revenue trends show early signs of stabilization.